You and everyone you've ever loved are slowly dissolving.
The equivalent of 9 holocausts worth of people die every year from curable diseases.
All the while, humanity spends 40X more on building Skynet and enough nuclear bombs to kill everyone at least 20 times.
Below are an assortment of crazy ideas to try to address this.
PEER-REVIEWED BY EXACTLY ZERO PEERS. CITED BY FEWER. STILL MATHEMATICALLY CORRECT.

6.65K DISEASES (95% CI: 5.70K DISEASES-8.24K DISEASES) DISEASES HAVE 0 FDA-APPROVED TREATMENTS. AT CURRENT TRIAL CAPACITY (15 DISEASES/YEAR (95% CI: 8 DISEASES/YEAR-30 DISEASES/YEAR) NEW FIRST TREATMENTS/YEAR), EXPLORING THE THERAPEUTIC SEARCH SPACE TAKES ~443 YEARS (95% CI: 324 YEARS-712 YEARS). REDIRECT 1% OF MILITARY SPENDING ($27.2B/YEAR) TO PRAGMATIC CLINICAL TRIALS. TRIAL CAPACITY JUMPS 12.3X (95% CI: 4.19X-61.3X). SEARCH SPACE EXPLORED IN ~36 YEARS (95% CI: 11.6 YEARS-77.2 YEARS) INSTEAD OF CENTURIES. AVERAGE TREATMENT REACHES PATIENTS 212 YEARS (95% CI: 135 YEARS-355 YEARS) SOONER. TIMELINE SHIFT SAVES 10.7B DEATHS (95% CI: 7.39B DEATHS-16.2B DEATHS), VALUED AT $84.8 QUADRILLION (95% CI: $62.4 QUADRILLION-$97.3 QUADRILLION). COST-EFFECTIVENESS: $0.0018 (95% CI: $0.0007-$0.0041)/DALY, 50.3KX (95% CI: 23.7KX-111.7KX) BETTER THAN BED NETS. EVEN AT 1% (95% CI: 0.1%-10%) PROBABILITY OF TREATY ADOPTION, RISK-ADJUSTED COST-EFFECTIVENESS REMAINS SUPERIOR TO THE BEST EXISTING GLOBAL HEALTH INTERVENTIONS. INCENTIVE ALIGNMENT BONDS ADDRESS POLITICAL FEASIBILITY BY TYING LEGISLATORS' CAREER INCENTIVES TO A PUBLIC VOTING SCORECARD.

GOVERNMENT SPENDING IS OPTIMIZED FOR LOBBYING INTENSITY, NOT NET SOCIETAL VALUE. PROGRAMS WITH 100:1 BENEFIT-COST RATIOS GET BILLIONS WHILE PROGRAMS WITH NEGATIVE RETURNS GET HUNDREDS OF BILLIONS. INCENTIVE ALIGNMENT BONDS FLIP THIS BY CREATING A CAPITAL POOL THAT REWARDS POLITICIANS (VIA CAMPAIGN SUPPORT AND POST-OFFICE OPPORTUNITIES) FOR FUNDING HIGH-NSV PROGRAMS OVER LOW-NSV ALTERNATIVES. THE RESULT: PUBLIC GOOD BECOMES PRIVATE PROFIT FOR BOTH INVESTORS AND ELECTED OFFICIALS.

REPRESENTATIVE DEMOCRACY SUFFERS FROM AN INESCAPABLE PRINCIPAL-AGENT PROBLEM WHERE ELECTED OFFICIALS' INCENTIVES DIVERGE FROM CITIZEN WELFARE. WISHOCRACY INTRODUCES RAPPA (RANDOMIZED AGGREGATED PAIRWISE PREFERENCE ALLOCATION), WHICH AGGREGATES CITIZEN PREFERENCES THROUGH COGNITIVELY TRACTABLE PAIRWISE COMPARISONS AND CREATES ACCOUNTABILITY VIA CITIZEN ALIGNMENT SCORES THAT CHANNEL ELECTORAL RESOURCES TOWARD POLITICIANS WHO ACTUALLY REPRESENT WHAT CITIZENS WANT.

WHAT'S THE MAXIMUM COST TO ACHIEVE ANY POLICY CHANGE THROUGH LEGAL DEMOCRATIC CHANNELS? $25B FOR THE US, $200B GLOBALLY. FOR HIGH-VALUE REFORMS LIKE MILITARY-TO-HEALTH REALLOCATION, THIS YIELDS ROI EXCEEDING 400,000:1.

ECONOMIC ANALYSIS OF A DECENTRALIZED FRAMEWORK FOR DRUG ASSESSMENT (DFDA). WITH $21.8B/YEAR IN PRAGMATIC TRIAL FUNDING, THE FRAMEWORK COULD SAVE 10.7B DEATHS (95% CI: 7.39B DEATHS-16.2B DEATHS) AND AVERT 565B DALYS (95% CI: 361B DALYS-877B DALYS) AT $0.841 (95% CI: $0.242-$1.75) PER DALY, WHILE GENERATING $58.6B (95% CI: $49.2B-$73.1B) IN ANNUAL R&D SAVINGS.
I BUILT PLATFORMS TO ANALYZE HEALTH DATA AT SCALE. CHRONIC ILLNESS REMAINS UNIMPRESSED.
AGGREGATED & ANALYZED TO DETERMINE EFFECTS OF FOODS, DRUGS, AND SUPPLEMENTS
COVERAGE FOR CONDITION/TREATMENT PAIRS USING OPEN-SOURCE PLATFORMS
OPEN-SOURCE PLATFORMS FOR HEALTH DATA ANALYSIS AND POLICY RESEARCH
WHAT IF CLINICAL TRIALS COST $500 INSTEAD OF $41,000 PER PARTICIPANT?
82× CHEAPER. 8× FASTER. 416M LIVES SAVED. HERE'S WHAT I'M BUILDING TO MAKE IT HAPPEN.

A system optimized for saving lives rather than avoiding lawsuits. 50,000+ observational studies analyzed. Meta-analyses for 90%+ of condition-treatment pairs. Treatment rankings for 100+ conditions. The current FDA approval process takes 10+ years and costs $2.6B per drug. During that time, between 11,000 and 115,000 people die who could have been saved if the drug had been approved immediately. There are roughly 1.16 quadrillion possible drug combinations we haven't tested. At the current pace, we'll finish testing them all in approximately never. The dFDA could accelerate clinical discovery by 80X. Which, if my math is correct, means we could map the entire space of possible treatments in about 45 minutes.

Redirect 1% of global military spending to health research. Save 416 million lives. 700× more effective than current spending. I sent this proposal to everyone with the power to implement it. They have enthusiastically ignored me. When your last name is Sinn, you take validation wherever you can find it.

Data-driven policy analysis. Articles like 'The War on Drugs Increases Drug Deaths' and 'We Spend More on Corporate Welfare Than Social Welfare.' 2 million people read these. The policy remains exactly the same. But I made some really compelling charts and I stand by them.

A DAO focused on clinical research. That's a lot of technical jargon, so let me translate: imagine if Wikipedia and a clinical trial had a baby that was raised by blockchain. The result is a platform where anyone can contribute to medical research without needing permission from a committee of very tired people in lab coats.



Aggregated Pairwise Preference Allocation. If that sounds like something from an economics paper written at 3 AM after too much coffee, you are correct. It's a mechanism for democratic resource allocation. Whether anyone will ever use it remains unclear. But the math is elegant and that has to count for something.


The Plutonium Kidz were born of a secret government program involving the testing of plutonium exposure on human subjects. Through these experiments three normal children were thus transformed into the Plutonium Kidz! The government program, regrettably, remains classified.
192+ PUBLICATIONS ON CLINICAL RESEARCH, POLICY ANALYSIS, AND THE OPTIMAL ALLOCATION OF SOCIETAL RESOURCES.

This paper introduces Wishocracy, a governance mechanism that employs Randomized Aggregated Pairwise Preference Allocation (RAPPA) to elicit and synthesize collective preferences for public resource allocation. By decomposing n-dimensional preference spaces into tractable pairwise comparisons, the mechanism reduces cognitive burden while preserving preference intensity.

We present the Predictor Impact Score (PIS), a novel composite metric operationalizing Bradford Hill causality criteria for automated signal detection from aggregated N-of-1 observational studies. Combined with pragmatic trial confirmation (based on evidence from 108+ embedded trials), this two-stage framework generates validated outcome labels at ~44x lower cost than traditional Phase III trials. This enables continuous, population-scale pharmacovigilance and precision dosing recommendations.